This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Astellas Pharma, Inc.
Drug Names(s): sepantronium bromide
Description: YM155 is a small molecule in injectable form that is expected to induce programmed cell death (apoptosis) in tumor tissue by suppressing survivin, an inhibitor of apoptosis.
Deal Structure: In April 2005, Yamanouchi and Fujisawa merged to form Astellas Pharma.
Pink Sheet Weekly Trademark Review May 12, 2015
Pink Sheet Weekly Trademark Review May 5, 2015
Additional information available to subscribers only: